Market intelligence, trend analysis and forecasts for the Pharma and Healthcare industries across the regions

Companies / Slovenia

Lek Expands Biopharmaceutical Capabilities

October 2006 | Company News Alert

Staking a prominent claim in the pharmaceutical sector experiencing the strongest growth, Slovenian firm Lek - part of Swiss firm Novartis' Sandoz generics division - has started construction of a new biopharmaceutical development centre just outside the country's capital, Ljubljana. BMI sees the announcement as strongly positive for Lek, which posted robust financial results last

Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.

[
: *
[
: *

Forgotten your password?

If you would like to subscribe to Emerging Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.

If you would like to take a trial to Emerging Europe Pharma & Healthcare Insight please click on the trial link below.

Free Trial To Pharmaceuticals & Healthcare Insight

TAKE A TRIAL >>
Related Insight Articles
Krka Enters Acquisition Market

Industry / Slovenia Slovenian drugmaker Krka is to make its first venture into Western Europe with the planned acquisition for German generics firm TAD Pharma in a deal reported to be worth EUR97mn (US$142.48mn).
November 2007
Krka Opens API Plant

Companies / Slovenia Leading Slovenian drugmaker Krka has officially opened its Sinteza 4 active pharmaceutical ingredient (API) production facility. The EUR80mn (US$107mn) plant will allow the firm to manufacture most of...
June 2007
Krka Maintains Positive Outlook

Companies / Slovenia On the back of impressive 2006 financial results, Slovenian drugmaker Krka is looking to further penetrate emerging markets, continue to upscale its R&D capabilities, get more products approved and...
February 2007
Krka, Servier Settle Patent Dispute

Companies / Slovenia Slovenia's Krka has reached an out-of-court settlement with French firm Servier over a generic version of the latter's perindopril - an ACE inhibitor for the treatment of hypertension. Under the deal,...
November 2006
Sales Up For Lek

Companies / Slovenia Outperforming its competitors, Slovenia firm Lek - part of the generics division of Swiss company Sandoz - has released financial results for the first half of 2006 in which sales increased by an impressive...
July 2006
Emerging Europe InsightEmerging Europe Channels Emerging Europe Countries


All material on this site is protected by international copyright laws and use of this site is subject to our Terms & Conditions.
© 2008 Business Monitor International Ltd
Site powered by WORKSsitebuilder CMS